List of Excipients in Branded Drug VENLAFAXINE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Trigen Laboratories LLC	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	13811-712	CELLULOSE, MICROCRYSTALLINE
Trigen Laboratories LLC	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	13811-712	FERROSOFERRIC OXIDE
Trigen Laboratories LLC	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	13811-712	HYPROMELLOSES
Trigen Laboratories LLC	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	13811-712	LACTOSE
Trigen Laboratories LLC	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	13811-712	MAGNESIUM STEARATE

Generic Drugs Containing VENLAFAXINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	venlafaxine hydrochloride	0093-0199	FERRIC OXIDE RED
Teva Pharmaceuticals USA Inc	venlafaxine hydrochloride	0093-0199	FERRIC OXIDE YELLOW
Teva Pharmaceuticals USA Inc	venlafaxine hydrochloride	0093-0199	LACTOSE MONOHYDRATE
Teva Pharmaceuticals USA Inc	venlafaxine hydrochloride	0093-0199	MAGNESIUM STEARATE
Teva Pharmaceuticals USA Inc	venlafaxine hydrochloride	0093-0199	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in VENLAFAXINE HYDROCHLORIDE?

# Of NDCs	Excipient
2	AKA3
4	ALCOHOL
33	AMMONIA
7	BUTYL ALCOHOL
6	CARNAUBA WAX

Venlafaxine Hydrochloride Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: August 28, 2026

Venlafaxine hydrochloride is a mature, multisource antidepressant with limited compound-level patent protection and continuing formulation opportunities. The highest-value excipient strategies involve extended-release multiparticulates, dissolution control, capsule differentiation, moisture management, and low-risk manufacturing platforms rather than new-molecule exclusivity.

Venlafaxine is marketed primarily as immediate-release tablets and extended-release capsules. The reference extended-release product, Effexor XR, uses coated spheroids to control release. Generic competition has substantially reduced the commercial value of the active pharmaceutical ingredient, but annual prescription volume, multiple strengths, and broad generic substitution support opportunities for excipient suppliers, contract manufacturers, and differentiated 505(b)(2) developers.

What is the FDA regulatory status of venlafaxine hydrochloride?

Venlafaxine hydrochloride is an FDA-approved small-molecule serotonin-norepinephrine reuptake inhibitor used for major depressive disorder. The immediate-release product is administered in divided doses, while the extended-release product is administered once daily.

Product type	Reference product	Active ingredient	Dosage form	Primary commercial status
Immediate release	Effexor	Venlafaxine hydrochloride	Tablet	Generic multisource
Extended release	Effexor XR	Venlafaxine hydrochloride	Extended-release capsule	Generic multisource
Generic ER	Multiple ANDA products	Venlafaxine hydrochloride	Extended-release capsule	Broad generic competition

The FDA Orange Book identifies approved products, therapeutic equivalence ratings, patents and regulatory exclusivities. Venlafaxine immediate-release and extended-release products are established generic categories, with multiple therapeutically equivalent products listed over time.[1]

The primary regulatory route for a new venlafaxine hydrochloride tablet or extended-release capsule is an abbreviated new drug application, provided the product demonstrates pharmaceutical equivalence, bioequivalence and compliance with applicable quality requirements. A reformulated product with a clinically meaningful delivery or administration advantage may require a 505(b)(2) application.

When does venlafaxine lose exclusivity?

Venlafaxine has lost meaningful compound-level exclusivity. The original venlafaxine patent, U.S. Patent No. 4,535,186, was filed in the 1980s and had a conventional term that ended before the current generic market developed.[2]

Effexor XR's commercial protection depended on later formulation and product patents rather than continuing active-ingredient exclusivity. The principal extended-release formulation patents are now historic barriers. Generic extended-release venlafaxine products have been approved in the U.S. for many years.

Protection category	Commercial position
Venlafaxine compound patent	Expired
Immediate-release product protection	Expired
Extended-release formulation protection	Historic patents expired or no longer a practical barrier to routine generic entry
FDA reference-product exclusivity	Expired
Current biosimilar exclusivity	Not applicable
Current commercial moat	Manufacturing know-how, regulatory execution, supply reliability and product differentiation

Patent expiration does not eliminate all technical barriers. Extended-release products still require control of particle size, coating weight, dissolution, dose uniformity, stability and bioequivalence. These are development and manufacturing barriers, not durable exclusivity rights.

What patents protect venlafaxine hydrochloride products?

The historic patent estate covered the active compound, pharmaceutical compositions and extended-release delivery approaches.

Compound patents

U.S. Patent No. 4,535,186 covered venlafaxine and related compounds. Its patent term has expired, leaving no current compound-level exclusivity for venlafaxine hydrochloride in the United States.[2]

Extended-release formulation patents

Effexor XR used a multiparticulate extended-release design. Relevant historic patent families covered coated spheroids and controlled-release formulations associated with venlafaxine. These patents were assigned to Wyeth, later part of Pfizer, and formed the basis of earlier generic litigation and regulatory disputes.

The commercial lesson is important: a multiparticulate product can be technically difficult to replicate even after formulation patents expire. A generic sponsor must reproduce the release profile without infringing any live claim and must establish bioequivalence against the reference product.

Orange Book status

The current Orange Book should be reviewed for the specific reference-listed product and strength before any launch or freedom-to-operate conclusion. Historic patents may remain visible in archived or product-specific records even when their expiration dates have passed. A patent listing does not itself prove enforceability or block generic approval after expiration.[1]

What excipients are used in venlafaxine hydrochloride immediate-release tablets?

Immediate-release venlafaxine tablets typically use standard oral solid-dose excipients. Exact compositions vary by manufacturer and strength.

Common excipient functions include:

Excipient class	Typical examples	Function
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate	Tablet mass and compressibility
Binder	Povidone, hypromellose	Granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Tablet breakup
Glidant	Colloidal silicon dioxide	Powder flow
Lubricant	Magnesium stearate, stearic acid	Ejection and tooling protection
Film former	Hypromellose	Appearance and handling
Colorant	Iron oxides, titanium dioxide	Identification and dose differentiation

The immediate-release formulation opportunity is usually cost reduction, process robustness or improved swallowing rather than release innovation. A direct-compression platform may reduce manufacturing steps, but venlafaxine hydrochloride loading, powder flow, electrostatic behavior and blend uniformity must be assessed at each strength.

Excipient substitution can affect dissolution and bioequivalence. Croscarmellose sodium, crospovidone, lubricant concentration and compression force can materially change disintegration. Magnesium stearate over-lubrication can reduce wetting and slow dissolution. These variables require comparative dissolution development rather than simple quantitative replacement.

What excipients are used in Effexor XR and generic extended-release capsules?

Effexor XR is based on coated spheroids filled into a hard gelatin capsule. The product label describes venlafaxine hydrochloride-containing spheroids with release-controlling coating materials and capsule shell excipients.[3]

A typical extended-release multiparticulate architecture includes:

1. Inert starter spheres or pellet cores.
2. A drug-containing layer.
3. A seal or barrier coat.
4. A functional extended-release membrane.
5. Capsule filling and strength-specific color coding.

Potential excipient categories include:

Formulation layer	Excipient options	Technical purpose
Core	Sugar spheres, microcrystalline cellulose pellets	Surface for drug loading
Drug layer	Povidone, hypromellose, hydroxypropyl cellulose	Adhesion and film formation
Release membrane	Ethylcellulose, methacrylate copolymers	Diffusion-controlled release
Pore former	Hypromellose, water-soluble polymers, salts	Adjustment of permeability
Anti-tacking agent	Talc, colloidal silicon dioxide	Prevents agglomeration during coating
Plasticizer	Triethyl citrate, polyethylene glycol	Film flexibility
Capsule	Gelatin or hypromellose	Encapsulation and identification

The exact composition of each approved generic product is manufacturer-specific. DailyMed labeling and FDA inactive-ingredient records are useful for screening, but neither source substitutes for the complete confidential manufacturing process or quantitative formulation record.[3,4]

How should an excipient strategy be designed for venlafaxine extended release?

The preferred strategy is a multiparticulate system with independent control of drug loading and membrane permeability. This architecture supports dose proportionality across strengths and reduces the risk that a single tablet defect causes a large release excursion.

Control the release mechanism

Ethylcellulose and methacrylate copolymers can provide sustained release through a water-permeable membrane. Release can be adjusted through:

• Polymer grade and viscosity.
• Coating weight gain.
• Pore-former concentration.
• Plasticizer level.
• Pellet size distribution.
• Drug-layer thickness.
• Curing conditions.
• Capsule fill mass.

The development target is a robust dissolution profile across physiologic pH conditions. Venlafaxine hydrochloride is water soluble, so an insufficiently dense or highly porous membrane can produce rapid release. The formulator must control coating uniformity and avoid a large initial burst.

Manage dose proportionality

Venlafaxine ER is commonly supplied in multiple strengths. A scalable platform can use a common pellet population with different capsule fill weights or different drug-layer loadings. A common-pellet platform may simplify supply and validation, but it must preserve dose uniformity and dissolution across strengths.

Address alcohol-induced dose dumping

Alcohol interaction risk is a material concern for modified-release products. The formulation should be evaluated in hydroalcoholic dissolution media and under stressed conditions. Polymer selection, pore structure and coating integrity determine whether alcohol accelerates drug release.

A formulation that performs well in aqueous media but releases rapidly in alcohol can create regulatory and labeling problems. Excipient selection should therefore be linked to alcohol-resistance testing from early development, not treated as a late-stage characterization exercise.

Control moisture and capsule stability

Venlafaxine hydrochloride formulations can be sensitive to moisture-related changes in powder behavior, coating performance and capsule stability. Commercial strategies include:

• Low-moisture excipient grades.
• High-barrier blister packaging.
• Desiccant-containing bottles.
• Moisture-controlled coating and filling rooms.
• Capsule shell selection based on water activity.
• Stability monitoring of dissolution, assay and degradation products.

The packaging strategy can be as important as the excipient choice. A lower-cost formulation that requires high-barrier packaging may lose its manufacturing advantage.

What formulation patents could create new commercial opportunities?

Most routine venlafaxine tablet and capsule products face limited patent value. New patent opportunities require a specific technical or clinical distinction.

Potential claim areas include:

Opportunity	Possible protected subject matter	Commercial potential
Abuse-resistant delivery	Physical or chemical barrier that limits crushing or extraction	Moderate, but clinical and regulatory value must be demonstrated
Pediatric administration	Taste-masked granules, sprinkle capsule or dispersible dosage form	Moderate
Low-dose titration	Small-strength multiparticulates or adjustable-dose system	Moderate
Improved tolerability	Modified exposure profile or reduced peak concentration	Potentially high if clinically supported
Alcohol-resistant ER	Membrane system with validated resistance to dose dumping	Moderate
Alternative capsule	HPMC capsule, tablet-in-capsule or sachet	Low to moderate
Fixed-dose combination	Venlafaxine with another active ingredient	High regulatory burden
Long-acting injectable	Depot or implant delivery	High development risk
Pediatric liquid	Stable oral solution or suspension	Commercially dependent on patient population

A patent directed only to a conventional excipient substitution is generally weak. Stronger claims would link a defined excipient range, manufacturing condition or microstructure to a measurable technical result, such as reduced alcohol sensitivity, narrower dissolution variability or improved stability.

How many patents cover venlafaxine hydrochloride today?

The practical answer is that venlafaxine's active-ingredient patent estate is exhausted, while current protection depends on product-specific formulation, process and use claims.

A patent-count exercise should separate:

• Expired compound patents.
• Expired Effexor XR formulation patents.
• Any still-active patents listed for a specific reference product.
• Unlisted formulation or process patents.
• Patents covering manufacturing intermediates.
• Third-party patents covering excipients, coating technologies or equipment.

A high raw patent count can misstate risk because many family members, continuations and expired records may cover the same technology. A claim-by-claim status review is more useful than counting documents.

Are there Paragraph IV challenges to venlafaxine hydrochloride?

Historic Paragraph IV litigation affected generic versions of Effexor XR. The main legal disputes involved whether generic extended-release products infringed formulation patents and whether those patents were valid. The market now contains multiple generic venlafaxine ER products, which indicates that historic patent barriers no longer prevent broad competition.

For a new entrant, the relevant risk is less likely to be the expired Effexor XR estate and more likely to involve:

• A later-filed process patent.
• A coating or pellet patent owned by an excipient or technology supplier.
• A formulation patent covering a specific dissolution profile.
• A method-of-use patent tied to a narrow patient population.
• Manufacturing equipment or scale-up know-how.

A Paragraph IV strategy remains relevant only if a proposed product could launch before the relevant patent expiration and the sponsor has a credible invalidity or noninfringement position. For routine venlafaxine ER, the commercial return may not justify aggressive litigation unless the product has a meaningful cost or market-share advantage.

What is the biosimilar risk for venlafaxine hydrochloride?

There is no biosimilar risk because venlafaxine hydrochloride is a chemically synthesized small molecule, not a biologic. Competition occurs through ANDAs and, for differentiated products, 505(b)(2) applications.

The competitive risks are generic substitution, price erosion, wholesaler concentration, shortage-driven switching and private-label supply. Regulatory complexity is lower than for biologics, but formulation replication and supply reliability remain important.

Which companies are competing in venlafaxine hydrochloride?

The market includes branded originator interests, large generic manufacturers, specialty generic companies and contract manufacturers. Historical generic suppliers have included Teva, Greenstone, Hikma, Zydus, Solco and other FDA-approved applicants, depending on product, strength and time period.

Market participation changes as applicants withdraw products, transfer ANDAs or lose commercial interest in low-margin strengths. The most relevant competitive variables are:

• Number of active suppliers by strength.
• Therapeutic-equivalence rating.
• Shortage history.
• API source concentration.
• Annualized unit volume.
• Payer and wholesaler contracting.
• Ability to supply both immediate-release and ER products.
• Cost of coating, pelletization and capsule filling.

No biosimilar entrants exist. The commercial battlefield is generic manufacturing and differentiated delivery.

What manufacturing and IP barriers affect venlafaxine ER?

The main barriers are process controls rather than active-ingredient availability.

Critical manufacturing steps include drug layering, fluid-bed coating, pellet classification, curing, capsule filling and dissolution testing. Key process risks include:

• Agglomeration during drug layering.
• Uneven membrane coating.
• Pellet attrition.
• Broad particle-size distribution.
• Capsule fill-weight variability.
• Delayed dissolution changes during stability.
• Scale-up differences between development and commercial coaters.

Manufacturing know-how can create a defensible commercial position even when patents are weak. A supplier with validated coating parameters, reliable starter cores and tight pellet specifications can reduce development time for multiple strengths.

Excipient suppliers can capture value by offering an integrated platform rather than commodity materials. Examples include prequalified coating systems, co-processed pellet excipients, low-moisture capsule shells, validated pore-former packages and technical support for dissolution matching.

What licensing deals are available for venlafaxine formulation technology?

Venlafaxine-specific licensing opportunities are limited because the active ingredient and principal reference products are mature. More realistic transactions involve platform technology:

• Multiparticulate coating systems.
• Taste-masking technology.
• Abuse-deterrent matrices.
• Capsule-in-capsule delivery.
• Pediatric sprinkle systems.
• Continuous coating and pelletization equipment.
• Excipient supplier development agreements.
• Contract development and manufacturing arrangements.

A platform license can be attractive if it provides a repeatable path to multiple molecules, not only venlafaxine. A molecule-specific license has weaker economics unless it includes a differentiated clinical label, protected formulation or exclusive market access.

How does venlafaxine compare with competing antidepressants?

Venlafaxine competes with generic selective serotonin reuptake inhibitors and other serotonin-norepinephrine reuptake inhibitors.

Product	Release options	Generic maturity	Excipient opportunity
Venlafaxine	IR tablet, ER capsule	High	Pellet coating, dose flexibility, pediatric and administration formats
Duloxetine	Delayed-release capsule	High but technically demanding	Enteric coating, acid protection, capsule filling
Desvenlafaxine	ER tablet	High	Matrix release, tablet robustness
Escitalopram	IR tablet, oral solution	High	Taste masking, liquid and low-dose formats
Fluoxetine	Capsule, tablet, solution	High	Liquid stability, taste masking and dose flexibility

Venlafaxine ER is technically more attractive than a simple immediate-release generic because its multiparticulate architecture requires controlled coating and dissolution performance. Duloxetine may present greater enteric-coating complexity, while desvenlafaxine may offer a simpler matrix-tablet manufacturing platform.

What generic launch scenarios exist for venlafaxine hydrochloride?

Three launch models are commercially plausible.

Low-cost ANDA launch

A sponsor uses conventional excipients and matches the reference dissolution and pharmacokinetic profile. This approach requires efficient API sourcing, high manufacturing utilization and competitive pricing.

Differentiated generic

A sponsor offers a clinically equivalent product with a practical administration benefit, such as a smaller capsule, improved swallowability, alternative capsule shell or sprinkle format. The regulatory pathway and labeling strategy determine whether the differentiation supports a premium.

505(b)(2) reformulation

A sponsor develops a new delivery system, liquid, pediatric product or modified exposure profile. This route can generate intellectual-property value but requires clinical, CMC and regulatory investment. The mature generic market limits the price premium available for incremental improvements.

What is the revenue exposure for venlafaxine hydrochloride?

Venlafaxine has meaningful prescription demand but limited branded revenue exposure. Most current value is distributed across generic manufacturers, API suppliers, excipient suppliers, wholesalers and pharmacies.

Revenue depends on:

• Total U.S. prescription volume.
• Generic reimbursement rates.
• Number of active suppliers.
• ER versus immediate-release mix.
• Strength-specific volume.
• Shortage and back-order conditions.
• Payer substitution policies.
• Export-market pricing.

A precise current revenue estimate requires a defined geography, product scope and reporting period. Public company filings generally do not isolate venlafaxine revenue at the product level. The more durable commercial opportunity is therefore in manufacturing efficiency, supply assurance and differentiated delivery technology.

Key Takeaways

• Venlafaxine hydrochloride has no meaningful active-ingredient patent exclusivity.
• Effexor XR formulation protection is primarily historic; generic ER competition is established.
• The strongest technical opportunity is a robust multiparticulate extended-release platform.
• Ethylcellulose, methacrylate copolymers, pore formers, plasticizers and anti-tacking agents are central formulation tools.
• Alcohol-resistant dissolution, moisture control and dose proportionality should be built into development.
• Immediate-release products offer limited formulation differentiation and are primarily cost-driven.
• Biosimilar risk does not apply because venlafaxine is a small molecule.
• Licensing value is more likely to reside in delivery platforms than in venlafaxine-specific rights.
• Commercial defensibility depends on manufacturing execution, supply reliability and regulatory equivalence.
• New patent value requires a measurable technical or clinical advantage, not a routine excipient substitution.

FAQs

Can venlafaxine hydrochloride be formulated as a tablet instead of a capsule?

Yes. Immediate-release venlafaxine is marketed as a tablet, and extended-release delivery can also be developed in tablet form. A tablet must demonstrate equivalent release behavior and bioequivalence where required.

Which coating polymer is most suitable for venlafaxine ER pellets?

Ethylcellulose and selected methacrylate copolymers are common starting points. The optimal polymer depends on permeability, coating weight, pore-former level, alcohol response, curing behavior and target dissolution.

Is venlafaxine hydrochloride suitable for a pediatric sprinkle product?

Potentially. Multiparticulates can support sprinkle administration, but taste masking, dose uniformity, stability, labeling and demonstration that the pellets are not crushed or chewed would be central development issues.

Can an excipient supplier patent a venlafaxine formulation?

Yes, if the formulation contains a novel and non-obvious technical combination. A claim based only on replacing one conventional excipient with another would generally provide limited protection.

Does venlafaxine hydrochloride require an enteric coating?

Not as a general requirement. Effexor XR uses extended-release multiparticulates rather than a conventional enteric-release concept. Enteric protection would need a specific pharmacokinetic, tolerability or stability rationale.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

2. United States Patent and Trademark Office. (1985). U.S. Patent No. 4,535,186: Substituted cyclohexanol derivatives. https://patents.google.com/patent/US4535186

3. Pfizer Laboratories. (2019). Effexor XR (venlafaxine hydrochloride) extended-release capsules: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

4. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

5. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly purified synthetic peptides. https://www.fda.gov/regulatory-information/search-fda-guidance-documents

6. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: General chapter <711>, dissolution. USP-NF.